公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2021 | Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence | Lu S.; JIN-YUAN SHIH ; Jang T.-W.; Liam C.-K.; Yu Y. | Advances in Therapy | 12 | 9 | |
2021 | Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3) | Popat S.; Liu G.; Lu S.; Song G.; Ma X.; CHIH-HSIN YANG | Future Oncology | 11 | 6 | |
2011 | Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach | Salto-Tellez M.; Tsao M.-S.; JIN-YUAN SHIH ; Thongprasert S.; Lu S.; Chang G.-C.; Au J.S.-K.; Chou T.-Y.; Lee J.-S.; Shi Y.-K.; Radzi A.; Kang J.-H.; Kim S.-W.; Tan S.-Y.; CHIH-HSIN YANG | Journal of Thoracic Oncology | 35 | 36 | |
2008 | Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region | Tay E.H.; Garland S.; Tang G.; Nolan T.; LI-MIN HUANG ; Orloski L.; Lu S.; Barr E. | International Journal of Gynecology and Obstetrics | 25 | 24 | |
2015 | Effects of cooking, retrogradation and drying on starch digestibility in instant rice making | Hsu R.J.C.; Chen H.-J. ; Lu S.; Chiang W. | Journal of Cereal Science | 32 | 26 | |
2021 | Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial | CHIH-HSIN YANG ; Mok T.S.K.; Lu S.; Nakagawa K.; Yamamoto N.; Shi Y.-K.; Zhang L.; Soo R.A.; Morita S.; Tamura T. | JTO Clinical and Research Reports | 0 | 0 | |
2022 | Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial | Lu S.; Wang Q.; Zhang G.; Dong X.; Yang C.-T.; Song Y.; Chang G.-C.; Lu Y.; Pan H.; Chiu C.-H.; Wang Z.; Feng J.; Zhou J.; Xu X.; Guo R.; Chen J.; Yang H.; Chen Y.; Yu Z.; Shiah H.-S.; Wang C.-C.; Yang N.; Fang J.; Wang P.; Wang K.; Hu Y.; He J.; Wang Z.; Shi J.; Chen S.; Wu Q.; Sun C.; Li C.; Wei H.; Cheng Y.; Su W.-C.; Hsia T.-C.; Cui J.; Sun Y.; Ou S.-H.I.; Zhu V.W.; CHIH-HSIN YANG | Journal of Thoracic Oncology | 72 | 51 | |
2022 | Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial | Majem M.; Goldman J.W.; John T.; Grohe C.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.V.; Lu S.; Li S.; Lee K.Y.; Akewanlop C.; CHONG-JEN YU ; de Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Atagi S.; Zeng L.; Kulkarni D.; Medic N.; Tsuboi M.; Herbst R.S.; Wu Y.-L. | Clinical Cancer Research | 15 | 9 | |
2021 | Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease | Chuang W.-L.; Hu T.-H.; Buggisch P.; Moreno C.; Su W.-W.; Biancone L.; Camargo M.; Hyland R.; Lu S.; Kirby B.J.; Dvory-Sobol H.; Osinusi A.; Gaggar A.; Peng C.-Y.; CHEN-HUA LIU ; Sise M.E.; Mangia A. | The American journal of gastroenterology | 7 | 6 | |
2008 | Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan | CHI-LING CHEN ; Yang HwaiI.; WEI-SHIUNG YANG ; CHUN-JEN LIU ; PEI-JER CHEN ; You S.; Wang L.; Sun C.; Lu S.; DING-SHINN CHEN ; Chen C. | Gastroenterology | 471 | 426 | |
2022 | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma | Zhu A.X.; Abbas A.R.; de Galarreta M.R.; Guan Y.; Lu S.; Koeppen H.; Zhang W.; CHIH-HUNG HSU ; He A.R.; Ryoo B.-Y.; Yau T.; Kaseb A.O.; Burgoyne A.M.; Dayyani F.; Spahn J.; Verret W.; Finn R.S.; Toh H.C.; Lujambio A.; Wang Y. | Nature Medicine | 108 | 115 | |
2020 | Osimertinib in resected EGFR-mutated non–small-cell lung cancer | Wu Y.-L.; Tsuboi M.; He J.; John T.; Grohe C.; Majem M.; Goldman J.W.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.-V.; Lu S.; Lee K.-Y.; Akewanlop C.; CHONG-JEN YU ; de Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Hodge R.; Atasoy A.; Rukazenkov Y.; Herbst R.S. | New England Journal of Medicine | 1028 | 800 | |
2009 | Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses | CHUN-JEN LIU ; Chuang W.; Lee C.; Yu M.; Lu S.; Wu S.; Liao L.; CHI-LING CHEN ; Kuo H.; Chao Y.; Tung S.; Yang S.; JIA-HORNG KAO ; CHEN-HUA LIU ; Su W.; Lin C.; YUNG-MING JENG ; PEI-JER CHEN ; DING-SHINN CHEN | Gastroenterology | 182 | 157 | |
2019 | A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas | CHIA-CHI LIN ; Arkenau H.-T.; Lu S.; Sachdev J.; de Castro Carpe?o J.; Mita M.; Dziadziuszko R.; Su W.-C.; Bobilev D.; Hughes L.; Chan J.; Zhang Z.-Y.; Weiss G.J. | British Journal of Cancer | 17 | 12 | |
2021 | A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer | Wu Y.-L.; Tsuboi M.; John T.; Grohe C.; Majem M.; Goldman J.W.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.-V.; Lu S.; Lee K.-Y.; Akewanlop C.; CHONG-JEN YU ; De Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Hodge R.; Atasoy A.; Rukazenkov Y.; Herbst R.S. | Future Oncology | 3 | 1 | |
2022 | Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC | Wu Y.-L.; John T.; Grohe C.; Majem M.; Goldman J.W.; Kim S.-W.; Kato T.; Laktionov K.; Vu H.V.; Wang Z.; Lu S.; Lee K.Y.; Akewanlop C.; CHONG-JEN YU ; de Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Atasoy A.; Herbst R.S.; Tsuboi M. | Journal of Thoracic Oncology | 87 | 63 | |
2021 | Relationship between renal function and metal exposure of residents living near the No. 6 Naphtha Cracking Complex: A cross-sectional study | Yuan T.-H.; Jhuang M.-J.; Yeh Y.-P.; Chen Y.-H.; Lu S.; CHANG-CHUAN CHAN | Journal of the Formosan Medical Association | 12 | 8 | |
2020 | Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial | CHIH-HSIN YANG ; Camidge D.R.; Yang C.-T.; Zhou J.; Guo R.; Chiu C.-H.; Chang G.-C.; Shiah H.-S.; Chen Y.; Wang C.-C.; Berz D.; Su W.-C.; Yang N.; Wang Z.; Fang J.; Chen J.; Nikolinakos P.; Lu Y.; Pan H.; Maniam A.; Bazhenova L.; Shirai K.; Jahanzeb M.; Willis M.; Masood N.; Chowhan N.; Hsia T.-C.; Jian H.; Lu S. | Journal of Thoracic Oncology | 87 | 75 | |
2017 | A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer | Soh S.X.; Siddiqui F.J.; Allen J.C.; Kim G.W.; Lee J.C.; Yatabe Y.; Soda M.; Mano H.; Soo R.A.; Chin T.-M.; Ebi H.; Yano S.; Matsuo K.; Niu X.; Lu S.; Isobe K.; JIH-HSIANG LEE ; CHIH-HSIN YANG ; Zhao M.; Zhou C.; Lee J.-K.; Lee S.-H.; Lee J.Y.; Ahn M.-J.; Tan T.J.; Tan D.S.; Tan E.-H.; Ong S.T.; Lim W.-T. | Oncotarget | 14 | 12 | |
2020 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG ; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. | The Lancet Respiratory Medicine | 161 | 128 | |